Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

NCT ID: NCT04502316

Last Updated: 2026-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-26

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Summary:

The CVRx REBALANCE Registry includes patients who have been implanted with the Barostim System. Up to 5,000 patients will be enrolled. Data should be obtained from evaluations taken prior to implant, at implant, and every six months after device implant, up to the 36-month visit at which time each patient will be exited from the registry.

Enrollment data are collected retrospectively after consent and Barostim implant; post-enrollment data are collected prospectively from standard of care follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Barostim™ System

Implantation of the Barostim™ System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients can be included in the registry if they were implanted with a de novo Barostim System. Patients must sign an informed consent form after implantation with the Barostim System in order to participate in the registry.

Indications:

The Barostim System is indicated for the improvement of symptoms of heart failure - quality of life, six-minute hall walk and functional status - for patients who remain symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III or Class II (who had a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, a NT-proBNP \< 1600 pg/ml and excluding patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.

Contraindications:

* Bilateral carotid bifurcations located above the level of the mandible
* Baroreflex failure or autonomic neuropathy
* Uncontrolled, symptomatic cardiac bradyarrhythmias
* Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%
* Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
* Known allergy to silicone or titanium
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CVRx, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Grandview Medical Center

Birmingham, Alabama, United States

Site Status

Chan Heart Rhythm Institute

Mesa, Arizona, United States

Site Status

Akil Loli Consulting LLC

Phoenix, Arizona, United States

Site Status

Cabrillo Cardiology Research Group

Oxnard, California, United States

Site Status

COR Healthcare Medical Associates

Torrance, California, United States

Site Status

Aurora Denver Cardiology Associates

Aurora, Colorado, United States

Site Status

South Denver Cardiology Associates, P.C.

Littleton, Colorado, United States

Site Status

Medstar Health Research Insitutute

Washington D.C., District of Columbia, United States

Site Status

The George Washington University Medical Faculty Associates

Washington D.C., District of Columbia, United States

Site Status

Orlando Cardiac & Vascular Specialists

Altamonte Springs, Florida, United States

Site Status

Orlando Heart and Vascular Institute

Altamonte Springs, Florida, United States

Site Status

Lakewood Cardiovascular

Bradenton, Florida, United States

Site Status

AMA Heart and Vascular

Bradenton, Florida, United States

Site Status

Cardiovascular Solutions Institute

Bradenton, Florida, United States

Site Status

Cardiac Care Group

Cape Coral, Florida, United States

Site Status

Daytona Heart Group

Daytona Beach, Florida, United States

Site Status

Florida Heart Rhythm Specialists

Fort Lauderdale, Florida, United States

Site Status

First Coast Cardiovascular Institute

Jacksonville, Florida, United States

Site Status

Premier Cardiology & Vascular Associates

Maitland, Florida, United States

Site Status

University of Miami

Miami, Florida, United States

Site Status

Naples Heart Rhythm Specialists, PA

Naples, Florida, United States

Site Status

AdventHealth Orlando

Orlando, Florida, United States

Site Status

Sarasota Memorial Research Institute (Sarasota Memorial Hospital)

Sarasota, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

Howard T. Tee, M.D., F.A.C.C., F.A.C.P.

Vero Beach, Florida, United States

Site Status

Florida Cardiology (Guardian Research Organization, LLC)

Winter Park, Florida, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Cardiovascular Medicine

Moline, Illinois, United States

Site Status

Sinai Hospital of Baltimore

Baltimore, Maryland, United States

Site Status

Capitol Cardiology Associates

Lanham, Maryland, United States

Site Status

HeartPlus Diagnostic Center

Jackson, Mississippi, United States

Site Status

DeGregorio Cardiology

Glen Ridge, New Jersey, United States

Site Status

Valley Hospital

Ridgewood, New Jersey, United States

Site Status

Cardio Vascular Health Associates

South River, New Jersey, United States

Site Status

Capital Cardiology

Albany, New York, United States

Site Status

Marian David, M.D., P.C

Kew Gardens, New York, United States

Site Status

Adam Budzikowski PC

Maspeth, New York, United States

Site Status

Advanced Cardiac Care

Ozone Park, New York, United States

Site Status

Cone Health

Greensboro, North Carolina, United States

Site Status

Stern Cardiovascular

Germantown, Tennessee, United States

Site Status

Austin Heart

Austin, Texas, United States

Site Status

Baylor Scott & White Research Institute

Dallas, Texas, United States

Site Status

Centra Heart & Vascular Institute

Lynchburg, Virginia, United States

Site Status

Carient Heart & Vascular

Manassas, Virginia, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Marshfield Medical Center - Weston

Weston, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

360059-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.